Bellicum Pharmaceuticals, Inc. (NASDAQ:BLCM) has been given an average recommendation of “Hold” by the eight research firms that are covering the company, MarketBeat Ratings reports. Two research analysts have rated the stock with a sell recommendation, one has given a hold recommendation and five have given a buy recommendation to the company. The average 1-year price objective among brokerages that have issued a report on the stock in the last year is $26.20.

A number of research firms have issued reports on BLCM. ValuEngine cut Bellicum Pharmaceuticals from a “sell” rating to a “strong sell” rating in a research note on Friday. Jefferies Group LLC reissued a “buy” rating and issued a $16.00 target price (down from $18.00) on shares of Bellicum Pharmaceuticals in a research note on Thursday, August 10th. Raymond James Financial, Inc. set a $18.00 target price on Bellicum Pharmaceuticals and gave the company a “buy” rating in a research note on Wednesday, August 9th. BidaskClub cut Bellicum Pharmaceuticals from a “sell” rating to a “strong sell” rating in a research note on Wednesday, August 2nd. Finally, Wells Fargo & Company reissued an “outperform” rating and issued a $31.00 target price on shares of Bellicum Pharmaceuticals in a research note on Tuesday, June 27th.

COPYRIGHT VIOLATION WARNING: This news story was originally posted by American Banking News and is the sole property of of American Banking News. If you are reading this news story on another domain, it was illegally stolen and republished in violation of U.S. & international copyright legislation. The original version of this news story can be read at https://www.americanbankingnews.com/2017/08/15/bellicum-pharmaceuticals-inc-nasdaqblcm-given-consensus-recommendation-of-hold-by-brokerages.html.

Shares of Bellicum Pharmaceuticals (BLCM) opened at 7.52 on Tuesday. The company has a 50-day moving average price of $11.21 and a 200 day moving average price of $12.28. The stock’s market capitalization is $249.86 million. Bellicum Pharmaceuticals has a 52 week low of $7.41 and a 52 week high of $23.11.

Bellicum Pharmaceuticals (NASDAQ:BLCM) last posted its earnings results on Tuesday, August 8th. The biopharmaceutical company reported ($0.74) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.65) by $0.09. Bellicum Pharmaceuticals had a negative net margin of 17,957.31% and a negative return on equity of 70.74%. During the same period last year, the firm earned ($0.61) earnings per share. Analysts forecast that Bellicum Pharmaceuticals will post ($3.00) earnings per share for the current fiscal year.

In other news, VP Ken Moseley sold 13,823 shares of the business’s stock in a transaction dated Thursday, July 13th. The stock was sold at an average price of $12.26, for a total value of $169,469.98. Following the sale, the vice president now directly owns 14,314 shares in the company, valued at $175,489.64. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, CFO Alan A. Musso sold 6,311 shares of the business’s stock in a transaction dated Thursday, May 25th. The shares were sold at an average price of $12.24, for a total value of $77,246.64. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 30,571 shares of company stock worth $367,295. Corporate insiders own 23.30% of the company’s stock.

Hedge funds have recently modified their holdings of the stock. American International Group Inc. raised its stake in shares of Bellicum Pharmaceuticals by 7.1% in the first quarter. American International Group Inc. now owns 12,902 shares of the biopharmaceutical company’s stock worth $159,000 after buying an additional 852 shares during the period. JPMorgan Chase & Co. raised its stake in shares of Bellicum Pharmaceuticals by 5.4% in the first quarter. JPMorgan Chase & Co. now owns 2,239,084 shares of the biopharmaceutical company’s stock worth $27,630,000 after buying an additional 114,483 shares during the period. Trexquant Investment LP purchased a new stake in shares of Bellicum Pharmaceuticals during the first quarter worth approximately $211,000. Ameriprise Financial Inc. raised its stake in shares of Bellicum Pharmaceuticals by 29.6% in the first quarter. Ameriprise Financial Inc. now owns 192,501 shares of the biopharmaceutical company’s stock worth $2,375,000 after buying an additional 43,955 shares during the period. Finally, Swiss National Bank raised its stake in shares of Bellicum Pharmaceuticals by 51.2% in the first quarter. Swiss National Bank now owns 44,300 shares of the biopharmaceutical company’s stock worth $547,000 after buying an additional 15,000 shares during the period. Institutional investors own 63.97% of the company’s stock.

Bellicum Pharmaceuticals Company Profile

Bellicum Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company. The Company is focused on discovering and developing cellular immunotherapies for various forms of cancer, including hematological cancers and solid tumors, as well as orphan inherited blood disorders. The Company uses its chemical induction of dimerization (CID) technology platform to engineer and then control components of the immune system.

Analyst Recommendations for Bellicum Pharmaceuticals (NASDAQ:BLCM)

Receive News & Ratings for Bellicum Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bellicum Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.